ArticleInternational journal of hematology2011
Telomeres and prognosis in patients with chronic lymphocytic leukaemia.
Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.Frontiers of medicine · 2016Pooled it
- Article
- Article
- Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023Review
- Targeting Telomere Biology in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2021Article
- Telomere Dysfunction in Chronic Lymphocytic Leukemia.Frontiers in oncology · 2020Review
- Variability within the humanOncoTargets and therapy · 2019Article
- Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.PloS one · 2019Article
- Article
- Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Article
- Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.Leukemia · 2015Article
- Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia.International journal of cancer and oncology · 2015Article
- The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.Journal of hematology & oncology · 2014Review
- Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.Translational oncology · 2013Article
- Telomere length in relation to immunological parameters in patients with renal cell carcinoma.PloS one · 2013Article
- Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.PloS one · 2013Article
- Telomere Length and Hematological Disorders: A Review.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, telomere length, telomerase activity, the mutation load of immunoglobulin variable heavy chain (IGHV) genes, and established prognostic factors were investigated in 78 patients with chronic lymphocytic leukaemia (CLL) to determine the impact of telomere biology on the pathogenesis of CLL. Telomere length was measured by an automated multi-colour flow-FISH, and an age-independent delta telomere length (ΔTL) was calculated. CLL with unmutated IGHV genes was associated with shorter telomeres (p = 0.002). Furthermore, we observed a linear correlation between the frequency of IGHV gene mutations and elongation of telomeres (r = 0.509, p < 0.001). With respect to prognosis, a threshold ΔTL of -4.2 kb was the best predictor for progression-free and overall survival. ΔTL was not significantly altered over time or with therapy. The correlation between the mutational load in IGHV genes and the ΔTL in CLL might reflect the initial telomere length of the putative cell of origin (pre- versus post-germinal center B cells). In conclusion, the ΔTL is a reliable prognostic marker for patients with CLL. Short telomeres and high telomerase activity as occurs in some patients with CLL with a worse prognosis might be an ideal target for treatment with telomerase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.